Core Insights - Medicus Pharma Ltd. has received approval from the UAE Department of Health to commence a Phase 2 clinical study (SKNJCT-004) for the non-invasive treatment of Basal Cell Carcinoma (BCC) of the skin [1][2] - The study will involve 36 participants across four clinical sites in the UAE, including Cleveland Clinic Abu Dhabi [2][3] - The clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy of two dose levels of D-MNA compared to a placebo [3][4] Clinical Study Details - The SKNJCT-004 study will randomize participants into three groups: a placebo group, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA [3] - The high-dose of 200μg D-MNA is the maximum dose used in the previous Phase 1 study (SKNJCT-001), which met its primary objective of safety and tolerability [4][5] - In the Phase 1 study, D-MNA was well tolerated with no serious adverse events, and six participants achieved complete responses [5] Ongoing and Future Studies - The company is also conducting the SKNJCT-003 Phase 2 clinical study in the United States, which began randomizing patients in August 2024 and has shown a positive interim analysis with over 60% clinical clearance [6][7] - The number of participants in the SKNJCT-003 study has been increased to 90, and the company is expanding clinical trial sites in Europe [7] Strategic Developments - Medicus Pharma has entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing a next-generation GnRH antagonist for prostate cancer patients [8][11] - The acquisition is subject to due diligence and regulatory approvals, with no guarantees on the completion of the transaction [11] Company Overview - Medicus Pharma Ltd. is focused on accelerating the clinical development of novel therapeutics and has a subsidiary, SkinJect Inc., dedicated to non-invasive treatments for basal cell skin cancer [9][10]